Zim Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024
−1.2%+3.2%−7.8%
−31.4%+5.8%−20.5%
−57.5%−7.0%−26.5%
−52.0%−29.5%−29.4%
−52.4%−29.4%−29.3%
+14.3%+5.6%+30.8%
+17.4%+5.7%+19.2%
+20.4%+152.8%−56.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ZIMLAB₹136.54

Zim Laboratories Limited

· Pharma & Health
₹ CrorePeersANUHPHRVALIANTLABAHCLALBERTDAVDWANBURYHALEOSLABSBAJAJHCARETHEMISMEDMcap ₹730 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-7.8+3.2-1.2—
EBITDA Growth—-20.5+5.8-31.4—
EBIT Growth—-26.5-7.0-57.5—
Net Income Growth—-29.4-29.5-52.0—
EPS Growth—-29.3-29.4-52.4—
Total Assets Growth—+30.8+5.6+14.3—
Total Equity Growth—+19.2+5.7+17.4—
Cash from Operations Growth—-56.6+152.8+20.4—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.